Protection of cotton rats against human parainfluenza virus type 3 by vaccination with a chimeric FHN subunit glycoprotein

1 Cancer and Infectious Disease Research and 2 Molecular Biology Research, The Upjohn Company, 301 Henrietta Street, Kalamazoo, Michigan 49001, U.S.A. 49001 A cotton rat model of experimental human parainfluenza virus type 3 (PIV-3) infection was used to examine the efficacy of FHN, a novel chimeric...

Full description

Saved in:
Bibliographic Details
Published inJournal of general virology Vol. 74; no. 3; pp. 471 - 477
Main Authors Brideau, R. J, Oien, N. L, Lehman, D. J, Homa, F. L, Wathen, M. W
Format Journal Article
LanguageEnglish
Published Reading Soc General Microbiol 01.03.1993
Society for General Microbiology
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:1 Cancer and Infectious Disease Research and 2 Molecular Biology Research, The Upjohn Company, 301 Henrietta Street, Kalamazoo, Michigan 49001, U.S.A. 49001 A cotton rat model of experimental human parainfluenza virus type 3 (PIV-3) infection was used to examine the efficacy of FHN, a novel chimeric glycoprotein which contains the extracellular regions of the fusion (F) and haemagglutinin—neuraminidase (HN) glycoproteins of PIV-3. The FHN protein was expressed in insect cells using a baculovirus vector system. FHN vaccination resulted in induction of neutralizing antibodies, was completely protective at doses of 100 ng, and was superior to vaccination with secreted forms F and HN proteins, or mixtures of the F and HN glycoproteins. In addition, FHN immunization induced lymphoproliferative responses in mice which were directed against both the F and HN glycoproteins. Fusion of the F and HN proteins into a single chimeric glycoprotein appeared to enhance the protective immune response compared to that elicited by the individual glycoproteins or mixtures of the two glycoproteins. Received 14 July 1992; accepted 19 October 1992.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0022-1317
1465-2099
DOI:10.1099/0022-1317-74-3-471